In-vivo and in-vitro evaluation of pharmacological activities of Ardisia solanacea leaf extract
Background The Bangladeshi rural and hilly areas people have long tradition to use various medicinal plants for treating different diseases. That’s why, the crude methanolic leaf extract of Ardisia solanacea with its different fractions (petroleum ether, carbon tetrachloride, n-hexane and chloroform fractions) were subjected to investigate bioactivities in swiss albino mice; namely analgesic, CNS, and Oral hypoglycemic activities, while in-vitro evaluation of cytotoxicity. Methods Central nervous system activity was investigated by various method such as Elevated plus maze, Hole board, Hole cross and Open field test apparatus. Analgesic activity was evaluated by both acetic acid induced and tail immersion method. Hypoglycemic activity was evaluated by oral glucose tolerance test and cytotoxicity was evaluated by Brine shrimp lethality bioassay. Results In CNS activity, among others fractions, ASCF fraction produced a significant anxiolytic activity in both elevated plus maze and Hole board test. During open-field test almost all the fractions of A. solanacea leaves extract display decreased locomotor activities that indicates significant sedative activity. The ASME and ASCF showed significant peripheral analgesic activity at a dose of 200 mg/kg and 400 mg/kg body weight (p < 0.05). In tail immersion method, among others extracts chloroform fractions exhibited significant (p < 0.05) elongation of reaction time 30 min after oral dose of 200 and 400 mg/kg body weight respectively. The methanolic and n-hexane extracts reduced blood glucose level significantly after 90 min with value of 53.94% and 48.15% respectively (p < 0.05). In case of cytotoxicity activity, among other fractions carbon tetrachloride fraction showed lowest $ LC_{50} $ values. Conclusions From the above results, it is clear that different fractions of A. solanacea showed significant pharmacological potentiality in different in-vitro and in-vivo study model. So, it will be very much possible source for an isolating lead compound for curing the numerous disorders..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Clinical phytoscience - 5(2019), 1 vom: 29. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Islam, Mohammad Rashedul [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Analgesic |
|---|
| Anmerkungen: |
© The Author(s). 2019 |
|---|
| doi: |
10.1186/s40816-019-0128-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR037863533 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR037863533 | ||
| 003 | DE-627 | ||
| 005 | 20230519072751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40816-019-0128-9 |2 doi | |
| 035 | |a (DE-627)SPR037863533 | ||
| 035 | |a (SPR)s40816-019-0128-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Islam, Mohammad Rashedul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-vivo and in-vitro evaluation of pharmacological activities of Ardisia solanacea leaf extract |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2019 | ||
| 520 | |a Background The Bangladeshi rural and hilly areas people have long tradition to use various medicinal plants for treating different diseases. That’s why, the crude methanolic leaf extract of Ardisia solanacea with its different fractions (petroleum ether, carbon tetrachloride, n-hexane and chloroform fractions) were subjected to investigate bioactivities in swiss albino mice; namely analgesic, CNS, and Oral hypoglycemic activities, while in-vitro evaluation of cytotoxicity. Methods Central nervous system activity was investigated by various method such as Elevated plus maze, Hole board, Hole cross and Open field test apparatus. Analgesic activity was evaluated by both acetic acid induced and tail immersion method. Hypoglycemic activity was evaluated by oral glucose tolerance test and cytotoxicity was evaluated by Brine shrimp lethality bioassay. Results In CNS activity, among others fractions, ASCF fraction produced a significant anxiolytic activity in both elevated plus maze and Hole board test. During open-field test almost all the fractions of A. solanacea leaves extract display decreased locomotor activities that indicates significant sedative activity. The ASME and ASCF showed significant peripheral analgesic activity at a dose of 200 mg/kg and 400 mg/kg body weight (p < 0.05). In tail immersion method, among others extracts chloroform fractions exhibited significant (p < 0.05) elongation of reaction time 30 min after oral dose of 200 and 400 mg/kg body weight respectively. The methanolic and n-hexane extracts reduced blood glucose level significantly after 90 min with value of 53.94% and 48.15% respectively (p < 0.05). In case of cytotoxicity activity, among other fractions carbon tetrachloride fraction showed lowest $ LC_{50} $ values. Conclusions From the above results, it is clear that different fractions of A. solanacea showed significant pharmacological potentiality in different in-vitro and in-vivo study model. So, it will be very much possible source for an isolating lead compound for curing the numerous disorders. | ||
| 650 | 4 | |a Phytochemicals |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Central nervous system |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Analgesic |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hypoglycemic |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytotoxicity |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Naima, Jannatul |4 aut | |
| 700 | 1 | |a Proma, Nawreen Monir |4 aut | |
| 700 | 1 | |a Hussain, Md. Saddam |4 aut | |
| 700 | 1 | |a Uddin, S. M. Naim |4 aut | |
| 700 | 1 | |a Hossain, Mohammed Kamrul |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical phytoscience |d Heidelberg : SpringerOpen, 2015 |g 5(2019), 1 vom: 29. Okt. |w (DE-627)SPR037862200 |w (DE-600)2834057-7 |x 2199-1197 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2019 |g number:1 |g day:29 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40816-019-0128-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2019 |e 1 |b 29 |c 10 | ||